Clinical trials of combination treatments incorporating PD-1 inhibitors with conventional chemotherapies [57], molecular targeted drugs such as PARP inhibitors (olaparib and cediranib) for solid tumors [58], or multi-kinase inhibitor (sunitinib) for RCC [59], focal radiation therapy, and cancer immunomodulators are now underway. This evidence concerns the gene PDCD1 and cancer.